AnaptysBio (ANAB) announced that GSK (GSK) has shared interim results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial investigating Jemperli (dostarlimab-gxly) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab-gxly alone compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometrial cancer. These data from GSK’s RUBY clinical trial are being shared in a European Society for Medical Oncology (ESMO) Virtual Plenary, presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer (25-28 March) in Tampa, Florida and published simultaneously in The New England Journal of Medicine. "We continue to be encouraged in the differentiated outcomes delivered by immuno-oncology antibodies discovered at AnaptysBio as GSK advances their development to treat multiple advanced solid tumors. The positive results from the RUBY trial represent a potential breakthrough for patients with primary advanced or recurrent endometrial cancer," said Daniel Faga, interim president and chief executive officer of AnaptysBio. "There is a potential significant royalty opportunity over time to AnaptysBio from Jemperli if this indication is approved, as well as from GSK’s ongoing Phase 3 trials, including of dostarlimab in first line ovarian cancer and, in combination with cobolimab, a TIM-3 antagonist, in second line NSCLC."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ANAB:
- AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial
- AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- AnaptysBio reports Q4 EPS (93c), consensus (96c)
- AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference